Stargardt Disease Therapeutics Market, By Drug Type (Emixustat, LBS-008), By Age Group (Children (Below17 Years), Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies Online Pharmacies), By Region (North America, Latin
Description
Stargardt Disease Therapeutics Market, By Drug Type (Emixustat, LBS-008), By Age Group (Children (Below17 Years), Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.
Market Dynamics
The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.
Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.
Key features of the study:
This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global Stargardt Disease Therapeutics Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .
Detailed Segmentation:
Global Stargardt Disease Therapeutics Market , By Drug Type:
Emixustat
LBS-008
Global Stargardt Disease Therapeutics Market , By Age Group:
Children (Below17 Years)
Adult (Above 17 Years)
Global Stargardt Disease Therapeutics Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Stargardt Disease Therapeutics Market , By Region:
North America
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
South Africa
Central Africa
North Africa
Company Profiles
Kubota Pharmaceutical Holdings Co., Ltd.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Stargazer Pharmaceuticals Inc.
Iveric Bio, Inc.
Sanofi S.A.
Alkeus Pharmaceuticals Inc.
Astellas Pharma Inc.
CHABiotech CO., Ltd
ReVision Therapeutics, Inc.
Lin BioScience, Inc.
Biogen Inc.
F. Hoffmann-La Roche AG
“*” marked represents similar segmentation in other categories in the respective section.
Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.
Market Dynamics
The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.
Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.
Key features of the study:
This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global Stargardt Disease Therapeutics Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .
Detailed Segmentation:
Global Stargardt Disease Therapeutics Market , By Drug Type:
Emixustat
LBS-008
Global Stargardt Disease Therapeutics Market , By Age Group:
Children (Below17 Years)
Adult (Above 17 Years)
Global Stargardt Disease Therapeutics Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Stargardt Disease Therapeutics Market , By Region:
North America
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
South Africa
Central Africa
North Africa
Company Profiles
Kubota Pharmaceutical Holdings Co., Ltd.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Stargazer Pharmaceuticals Inc.
Iveric Bio, Inc.
Sanofi S.A.
Alkeus Pharmaceuticals Inc.
Astellas Pharma Inc.
CHABiotech CO., Ltd
ReVision Therapeutics, Inc.
Lin BioScience, Inc.
Biogen Inc.
F. Hoffmann-La Roche AG
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
167 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Age Group
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Diagnosis of Stargardt Disease
- Treatment of Stargardt Disease
- Regulatory Scenario
- Key Developments
- Recent Approvals / Launches
- Merger, Acquisitions, and Agreement
- PEST Analysis
- Epidemiology
- 4. Global Stargardt Disease Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Impact on Overall the Healthcare Sector
- COVID-19 Epidemiology
- Supply and Demand Analysis
- COVID-19 Impact on Clinical Trials and Drug Development
- Initiatives Taken to Conduct Ongoing Clinical Trials
- 5. Global Stargardt Disease Therapeutics Market , By Drug Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Emixustat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- LBS-008
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Global Stargardt Disease Therapeutics Market , By Age Group, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Children (Below17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Adult (Above 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 7. Global Stargardt Disease Therapeutics Market , By Distribution Channel, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 8. Global Stargardt Disease Therapeutics Market , By Region, , 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- 9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Kubota Pharmaceutical Holdings Co., Ltd.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Stargazer Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Iveric Bio, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alkeus Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CHABiotech CO., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ReVision Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lin BioScience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 10. Section
- Research Methodology
- About us
- *Browse 35 market data tables and 30 figures on "Global Stargardt Disease Therapeutics Market” - Global forecast to 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
